MA2 Observation of Persistence Rates and Potential Cost Savings Associated With Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northern Ireland Clinical Practice
Abstract
Authors
M. Russell J. Timoshanko E. Smets G. Duncan A. Spandley S. Roskell